Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
A pilot study with cysteamine treatment was performed in three children with the nephropathic form of cystinosis. Two children underwent renal transplantation shortly before treatment. The aim of the study was to find a practicable form of application and a corresponding effective dose. Cysteamine in gelatine capsules together with 0.2% silicic acid as a dessicator turned out to be the most acceptable galenic form, compared to sirup or suppositories. Among three dosage regimens, the dosage of 50 mg/kg/day is effective as judged by the leucocyte cystine content, even if given in only three doses per day. No side effects of the cysteamine treatment (even at a dose of 90 mg/kg/day) were noted. Whether this treatment is preventing progression of disease will have to be examined either in transplanted patients by measuring non-renal parameters or in very young infants with cystinosis whose kidneys are not damaged yet.
D002675:Child, Preschool; D003543:Cysteamine / Q000008:administration & dosage / Q000627:therapeutic use*; D003553:Cystine / Q000378:metabolism; D003554:Cystinosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007223:Infant; D016030:Kidney Transplantation; D010865:Pilot Projects; D011183:Postoperative Complications / Q000188:drug therapy; D006435:Renal Dialysis
D003553:Cystine; D003543:Cysteamine